Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. plans to invest more than $1 billion to increase contract manufacturing in India over the next several years, the company announced Monday.
Lilly said the investment will strengthen its manufacturing and supply capabilities to support its evolving portfolio of drugs, including those for diabetes, obesity, Alzheimer’s disease, cancer and autoimmune conditions.
As part of the expansion plan, Lilly will establish a new manufacturing and quality hub in the southern India city of Hyderabad.
Lilly said it plans to tap into India’s skilled workforce for the new site, with recruitment for engineers, chemists, analytical scientists, quality-control and assurance experts, and managers beginning immediately.
The company does not currently operate its own manufacturing facility in India, but hosts several firms that manufacture drugs, vials and injectables on a contract basis.
Lilly began selling its blockbuster diabetes drug Mounjaro in India earlier this year. The country, which has one of the world’s largest populations of obese people, is expected to be a major market for weight-loss drugs in the coming years.
“Working with trusted contract manufacturers expands our capabilities to deliver life-changing medicines at greater scale—with quality always at the core,” Patrik Jonsson, Lilly’s executive vice president and president of Lilly International, said in written remarks. “This investment reaffirms our confidence in India as a hub for capability building within our global network.”
Lilly shares were up 1.2% in late morning trading Monday, to $849.96 each.
Please enable JavaScript to view this content.
Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.